Patients Prescribed Drugs Like Ozempic and Mounjaro Have Increased Over 300% May 14, 2023 Key Takeaways National spending for semaglutide, the peptide name for brand drugs like Ozempic and Wegovy, totaled $10.7B in 2021, the fourth highest across drug classes
This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next
The GLP-1 RA improves outcomes for obese patients with hidradenitis suppurativa, according to new research presented at the EADV Congress 2024
Mi celulitis ha disminuido significativamente y mi piel se siente mucho ms tonificada
Conclusions Semaglutide 2.4 mg is likely to be a short-term, cost-effective treatment option for adults who are overweight or have obesity without diabetes in Greece
This device delivers electrical stimulation to the tongue muscles to stabilize airway patency
